A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
44actual
Sites
17
Countries
Germany, Poland, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was terminated due to business decision. The decision to terminate the trial was not based on any safety concerns associated with PF-07054894.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-07 | actual | When the study began enrolling |
| Primary completion | 2025-11-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-11 | actual | The whole study's end, after follow-up |
| First posted | 2022-09-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis
Interventions
- Drug: PF-07054894
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Proportion of participants achieving clinical remission at Week 12 in participants with moderate to severe UC.
measured Week 12
Part B: Percent change from baseline in the mMS in participants with mild to moderate UC.
measured Week 12
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed